A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells.
Cancer immunotherapy
Hepatocellular carcinoma
Immune-related genes (IRGs)
Prognostic model
Tumor immune microenvironment(TIME)
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Apr 2022
09 Apr 2022
Historique:
received:
12
07
2021
accepted:
25
03
2022
entrez:
10
4
2022
pubmed:
11
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
The combined application of immune cells and specific biomarkers related to the tumor immune microenvironment has a better predictive value for the prognosis of HCC. The purpose of this study is to construct a new prognostic model based on immune-related genes that regulate cross-talk between immune and tumor cells to assess the prognosis and explore possible mechanisms. The immune cell abundance ratio of 424 cases in the TCGA-LIHC database is obtained through the CIBERSORT algorithm. The differential gene analysis and cox regression analysis is used to screen IRGs. In addition, the function of IRGs was preliminarily explored through the co-culture of M2 macrophages and HCC cell lines. The clinical validation, nomogram establishment and performing tumor microenvironment score were validated. We identified 4 immune cells and 9 hub genes related to the prognosis. Further, we identified S100A9, CD79B, TNFRSF11B as an IRGs signature, which is verified in the ICGC and GSE76427 database. Importantly, IRGs signature is closely related to the prognosis, tumor microenvironment score, clinical characteristics and immunotherapy, and nomogram combined with clinical characteristics is more conducive to clinical promotion. In addition, after co-culture with M2 macrophages, the migration capacity and cell pseudopod of MHCC97H increased significantly. And CD79B and TNFRSF11B were significantly down-regulated in MHCC97H, Huh7 and LM3, while S100A9 was up-regulated. We constructed an IRGs signature and discussed possible mechanisms. The nomogram established based on IRGs can accurately predict the prognosis of HCC patients. These findings may provide a suitable therapeutic target for HCC.
Sections du résumé
BACKGROUND
BACKGROUND
The combined application of immune cells and specific biomarkers related to the tumor immune microenvironment has a better predictive value for the prognosis of HCC. The purpose of this study is to construct a new prognostic model based on immune-related genes that regulate cross-talk between immune and tumor cells to assess the prognosis and explore possible mechanisms.
METHOD
METHODS
The immune cell abundance ratio of 424 cases in the TCGA-LIHC database is obtained through the CIBERSORT algorithm. The differential gene analysis and cox regression analysis is used to screen IRGs. In addition, the function of IRGs was preliminarily explored through the co-culture of M2 macrophages and HCC cell lines. The clinical validation, nomogram establishment and performing tumor microenvironment score were validated.
RESULTS
RESULTS
We identified 4 immune cells and 9 hub genes related to the prognosis. Further, we identified S100A9, CD79B, TNFRSF11B as an IRGs signature, which is verified in the ICGC and GSE76427 database. Importantly, IRGs signature is closely related to the prognosis, tumor microenvironment score, clinical characteristics and immunotherapy, and nomogram combined with clinical characteristics is more conducive to clinical promotion. In addition, after co-culture with M2 macrophages, the migration capacity and cell pseudopod of MHCC97H increased significantly. And CD79B and TNFRSF11B were significantly down-regulated in MHCC97H, Huh7 and LM3, while S100A9 was up-regulated.
CONCLUSION
CONCLUSIONS
We constructed an IRGs signature and discussed possible mechanisms. The nomogram established based on IRGs can accurately predict the prognosis of HCC patients. These findings may provide a suitable therapeutic target for HCC.
Identifiants
pubmed: 35397536
doi: 10.1186/s12885-022-09465-9
pii: 10.1186/s12885-022-09465-9
pmc: PMC8994280
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Front Immunol. 2018 Apr 13;9:622
pubmed: 29706952
Ann Anat. 2020 Jan;227:151409
pubmed: 31400446
World J Gastroenterol. 2020 Oct 14;26(38):5759-5783
pubmed: 33132633
Int Immunopharmacol. 2020 Jul;84:106574
pubmed: 32413741
Cancer Lett. 2018 Mar 28;417:35-46
pubmed: 29242097
Clin Immunol. 2017 Oct;183:158-166
pubmed: 28847516
World J Gastroenterol. 2018 Aug 21;24(31):3500-3512
pubmed: 30131656
Int J Biol Sci. 2020 Apr 25;16(11):1956-1971
pubmed: 32398963
J Urol. 2006 Oct;176(4 Pt 1):1326-31
pubmed: 16952623
Int J Cancer. 2021 Mar 1;148(5):1233-1244
pubmed: 33205453
Dig Liver Dis. 2018 Nov;50(11):1115-1123
pubmed: 30217732
Hepatology. 2021 Jul;74(1):214-232
pubmed: 33615520
Exp Cell Res. 2015 Jun 10;334(2):228-38
pubmed: 25907296
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
J Biol Chem. 1998 Jun 5;273(23):14363-7
pubmed: 9603945
Front Immunol. 2020 Jun 24;11:1326
pubmed: 32670292
J Immunother Cancer. 2016 Jul 19;4:40
pubmed: 27437104
Oncol Lett. 2018 Dec;16(6):7158-7165
pubmed: 30546452
J Hepatol. 2018 Aug;69(2):385-395
pubmed: 29572095
PLoS One. 2016 Jun 09;11(6):e0157022
pubmed: 27280887
Front Immunol. 2017 Dec 13;8:1774
pubmed: 29326691
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Cancer Med. 2020 Oct;9(20):7440-7452
pubmed: 32815653
Genomics. 2020 May;112(3):2640-2646
pubmed: 32087243
World J Gastroenterol. 2019 Jul 7;25(25):3151-3167
pubmed: 31333308
Sci Rep. 2015 Dec 07;5:17868
pubmed: 26639163
J Immunol. 2013 Aug 1;191(3):1126-35
pubmed: 23817422
Endocr Relat Cancer. 2019 Jun;26(6):601-614
pubmed: 30965283
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Genome Med. 2014 Oct 28;6(10):80
pubmed: 25419236
Immunol Rev. 2006 Jun;211:214-24
pubmed: 16824130
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Nat Commun. 2018 Jul 3;9(1):2574
pubmed: 29968710
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4126-31
pubmed: 12651942
Cells. 2019 Sep 14;8(9):
pubmed: 31540045
Int J Mol Sci. 2017 Feb 14;18(2):
pubmed: 28216578
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Front Immunol. 2020 Feb 07;10:3127
pubmed: 32117201
Front Immunol. 2019 Nov 05;10:2525
pubmed: 31787967
Front Immunol. 2020 Jun 12;11:1203
pubmed: 32595648
Immunol Rev. 2006 Jun;211:8-22
pubmed: 16824113
J Cancer Res Clin Oncol. 2013 Apr;139(4):669-79
pubmed: 23307318
Cancer Immunol Immunother. 2021 Apr;70(4):967-979
pubmed: 33089373
Cancer Lett. 2019 Oct 10;462:23-32
pubmed: 31356845
Int J Cancer. 2010 Mar 1;126(5):1263-74
pubmed: 19728335
Aging (Albany NY). 2020 Mar 25;12(6):5479-5499
pubmed: 32213661
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Biomed Pharmacother. 2018 Jul;103:262-271
pubmed: 29656182
Immunity. 2014 Dec 18;41(6):886-97
pubmed: 25526304
J Hematol Oncol. 2019 May 29;12(1):53
pubmed: 31142326
Nucleic Acids Res. 2016 Jan 4;44(D1):D457-62
pubmed: 26476454
Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):97-106
pubmed: 11396639
Immunol Res. 2014 May;58(2-3):234-9
pubmed: 24791905
CA Cancer J Clin. 2020 Jul;70(4):313
pubmed: 32767693
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
Cancer Cell Int. 2019 Mar 25;19:71
pubmed: 30962765